We recently mentioned a product called DiaPort from Roche, invented way back in 1998, which insulin researchers have been talking about lately as a possible alternative to the implantable insulin pump! Say what? you may ask. What makes this injection port with internal tubing so powerful? Especially when there’s a newer product called iPort that seems to do the same thing, possibly more elegantly?
Well, the DiaPort must be surgically implanted, and its advantage is…
Read more »
Last week, the New York Chapter of the Juvenile Diabetes Research Foundation hosted their annual research briefing. Many chapters around the country host similar research briefings, and I was excited to find out that our local meeting would feature Dr. Sanjoy Dutta, Director of Glucose Control Therapies within the Treatment Therapies Program.
I want to note that although there’s been a lot of controversy surrounding the addition of treatment goals to JDRF’s mission, I whole-heatedly…
Read more »
A couple of weeks ago, we hosted our very first DiabetesMine Book Review Giveaway — a smashing success! — and our winner took us fully by surprise. In fact, she reminded us that outside the cocoon of the DOC, where online cheerleading and pats on the back are common fare, there are plenty of people fighting for their lives with this disease.
Our winner was Audrie Eckerle, a 20-year-old type 1 from Idaho, who has…
Read more »
{Note: this is second in a two-part series aimed not only at patients, but those in the Pharma industry as well.}
I was interviewed the other day for an upcoming story about Sanofi-Aventis’ new strategy to not just offer individual diabetes products, but become a “full diabetes management vendor.” They are not alone. Medtronic, Roche, Bayer, Abbott and others are among the big industry players talking about more of a “systems approach” to diabetes as…
Read more »
